GB0428173D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB0428173D0
GB0428173D0 GBGB0428173.9A GB0428173A GB0428173D0 GB 0428173 D0 GB0428173 D0 GB 0428173D0 GB 0428173 A GB0428173 A GB 0428173A GB 0428173 D0 GB0428173 D0 GB 0428173D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0428173.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0428173.9A priority Critical patent/GB0428173D0/en
Publication of GB0428173D0 publication Critical patent/GB0428173D0/en
Priority to JP2007547617A priority patent/JP2008525394A/ja
Priority to EP05818623A priority patent/EP1904487A2/fr
Priority to PCT/GB2005/004876 priority patent/WO2006067392A2/fr
Priority to CNA2005800444016A priority patent/CN101087781A/zh
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
GBGB0428173.9A 2004-12-23 2004-12-23 Compounds Ceased GB0428173D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0428173.9A GB0428173D0 (en) 2004-12-23 2004-12-23 Compounds
JP2007547617A JP2008525394A (ja) 2004-12-23 2005-12-16 化合物
EP05818623A EP1904487A2 (fr) 2004-12-23 2005-12-16 Derives de l'indole pour le traitement de la tuberculose
PCT/GB2005/004876 WO2006067392A2 (fr) 2004-12-23 2005-12-16 Composes
CNA2005800444016A CN101087781A (zh) 2004-12-23 2005-12-16 用于治疗肺结核的吲哚衍生物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0428173.9A GB0428173D0 (en) 2004-12-23 2004-12-23 Compounds

Publications (1)

Publication Number Publication Date
GB0428173D0 true GB0428173D0 (en) 2005-01-26

Family

ID=34113122

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0428173.9A Ceased GB0428173D0 (en) 2004-12-23 2004-12-23 Compounds

Country Status (5)

Country Link
EP (1) EP1904487A2 (fr)
JP (1) JP2008525394A (fr)
CN (1) CN101087781A (fr)
GB (1) GB0428173D0 (fr)
WO (1) WO2006067392A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314732B2 (en) 2000-02-17 2008-01-01 Tfk Inc. Drug and manufacturing method of same
FR2967672B1 (fr) * 2010-11-22 2012-12-28 Sanofi Aventis Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
WO2013055674A1 (fr) * 2011-10-10 2013-04-18 The University Of Toledo Méthode de traitement d'infections
WO2014037900A1 (fr) * 2012-09-07 2014-03-13 Novartis Ag Dérivés d'indole carboxamide et leurs utilisations
CN112250627B (zh) 2014-10-06 2024-02-02 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
WO2017173274A1 (fr) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
RS62670B1 (sr) 2016-09-30 2021-12-31 Vertex Pharma Modulator transmembranskog regulatora provodnosti cistične fibroze, farmaceutske kompozicije, metode lečenja i proces izrade modulatora
MX2019006637A (es) 2016-12-09 2019-08-21 Vertex Pharma Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador.
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
CA3071278A1 (fr) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated Procedes de preparation de composes de pyrrolidine
CN111479805B (zh) 2017-08-29 2024-08-13 罗格斯新泽西州立大学 治疗性吲唑
WO2019046465A2 (fr) * 2017-08-29 2019-03-07 Rutgers, The State University Of New Jersey Indoles thérapeutiques
CA3078893A1 (fr) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Formes cristallines et compositions de modulateurs de cftr
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (fr) 2018-04-13 2019-10-17 Alexander Russell Abela Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
US11807644B2 (en) * 2020-05-12 2023-11-07 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2631730B2 (ja) * 1988-12-20 1997-07-16 コニカ株式会社 カブリの発生が抑えられたハロゲン化銀写真感光材料
US5866594A (en) * 1995-08-04 1999-02-02 Otsuka Kagaku Kabushiki Kaisha Indole-2-carboxylate derivatives and fungicidal compositions for agricultural or horticultural use containing the derivatives as active component
US6077812A (en) * 1997-02-26 2000-06-20 Fmc Corporation Cycloimido-substituted benzofused heterocyclic herbicides
GB9716657D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
JP4589529B2 (ja) * 1997-12-24 2010-12-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Xa因子阻害剤としてのインドール誘導体
GB9902459D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
US6372752B1 (en) * 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof

Also Published As

Publication number Publication date
WO2006067392A2 (fr) 2006-06-29
WO2006067392A3 (fr) 2007-03-08
CN101087781A (zh) 2007-12-12
JP2008525394A (ja) 2008-07-17
EP1904487A2 (fr) 2008-04-02

Similar Documents

Publication Publication Date Title
GB0405933D0 (en) Compounds
EP1737831A4 (fr) Composes neurologiquement actifs
GB0405937D0 (en) Compounds
GB0428173D0 (en) Compounds
EP1755617A4 (fr) Composés solubles dans des perfluorocarbones
GB0405193D0 (en) Compounds
GB0405272D0 (en) Compounds
GB0405267D0 (en) Compounds
GB0405101D0 (en) Compounds
GB0401269D0 (en) Compounds
GB0408772D0 (en) Compounds
GB0405280D0 (en) Compounds
GB0405893D0 (en) Compounds
GB0403593D0 (en) Compounds
GB0406916D0 (en) Compounds
GB0403595D0 (en) Compounds
GB0403267D0 (en) Compounds
GB0401657D0 (en) Compounds
GB0406918D0 (en) Compounds
GB0404081D0 (en) Compounds
GB0404083D0 (en) Compounds
GB0404084D0 (en) Compounds
GB0404104D0 (en) Compounds
GB0404215D0 (en) Compounds
GB0405099D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)